Skip to content
Register
Log In
Register
Log In
SCIAXIS
  • Explore
    • Case Report
    • Clinical Trial
    • Review Article
    • New Technology
  • MedShots
  • Quiz Snippet
  • Podcast
  • Explore
    • Case Report
    • Clinical Trial
    • Review Article
    • New Technology
  • MedShots
  • Quiz Snippet
  • Podcast

Day: May 12, 2023

Integrated Outpatient Palliative Care Versus Standard Care In Patients With Parkinson Disease And Related Disorders

Parkinson’s disease (PD) affects 1 – 2% of the population above 65 years of age and has consequences on quality of life (QoL). PD and related disorders (PDRD) tend to have additional symptoms contributing to worse prognosis

Recognizing The Risk Loci For Parkinson’s Disease In Asians

Previous studies have identified several familial PD genes such as SNCA and LRRK2 in the European population. However, records of any comparative study to evaluate the extent of genetic risk between the Asian and European

Prevention of Post-Stroke Epilepsy with Double Dose Statin Therapy

One of the major causes of epilepsy is stroke and the incidence of the newly diagnosed, post-stroke epilepsy (PSE) has been found to be 3%−45% in elderly patients. Previous studies have suggested that statin therapy may result

Is Adjunctive Interpersonal and Social Rhythm Therapy Beneficial for Patients with Bipolar Disorder?

Interpersonal and social rhythm therapy in the treatment of bipolar disorder can assist patients in reducing the stressors leading to acute episodes. The ideal treatment for bipolar disorder includes treatment of an episode

Effects of Bipolar Disorder and Valproate Treatment on Striatal Dopamine Transporters

The dopamine transporter regulates the reuptake of extracellular dopamine into presynaptic neurons and its dysfunction could lead to mood and behavior abnormalities as observed in bipolar disorder. Previously conducted

Long-Term Management of Bipolar Disorder Using Paliperidone Palmitate

Bipolar disorder patients demonstrate a high rate of medication non-adherence which ranges anywhere between 20% to 60%. Long acting injectable (LAI) drugs are considered to possess the potential to manage this non-adherence

Next →
SCIAXIS
Instagram Youtube Facebook Pinterest-p
Get our wellness newsletter

Maximize the informational quality of your email inbox by selectively subscribing to evidence-based health and wellness resources that are informed by rigorous scientific research and medical expertise.

Your privacy is important to us

  • About
  • Our Approach
  • Take a look at our content
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Editorial Policy
  • About
  • Our Approach
  • Take a look at our content
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Editorial Policy

© 2020-2022 HealthSciaxis a Sciaxis Company. All rights reserved. Our website services, content, and products are for informational purposes only. HealthSciaxis does not provide medical advice, diagnosis, or treatment. See additional information.